Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of “Buy” from Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS) has earned an average recommendation of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $25.67.

A number of analysts have recently commented on the stock. Oppenheimer boosted their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Thursday, January 23rd. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Finally, JMP Securities assumed coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They set an “outperform” rating and a $26.00 target price for the company.

Astria Therapeutics Stock Down 2.1 %

ATXS stock opened at $7.45 on Friday. The stock has a market capitalization of $420.43 million, a P/E ratio of -3.56 and a beta of 0.67. The firm has a 50-day simple moving average of $8.70 and a 200-day simple moving average of $10.34. Astria Therapeutics has a 52 week low of $7.16 and a 52 week high of $16.90.

Institutional Trading of Astria Therapeutics

Several hedge funds have recently made changes to their positions in the company. FMR LLC grew its stake in shares of Astria Therapeutics by 29.2% in the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after buying an additional 1,767,714 shares during the period. RA Capital Management L.P. boosted its position in shares of Astria Therapeutics by 1.2% during the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after purchasing an additional 61,457 shares during the period. Vestal Point Capital LP boosted its position in shares of Astria Therapeutics by 23.1% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after purchasing an additional 750,000 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Astria Therapeutics by 2.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 322,576 shares of the biotechnology company’s stock worth $2,884,000 after purchasing an additional 8,311 shares during the period. Finally, Redmile Group LLC purchased a new position in shares of Astria Therapeutics during the 3rd quarter worth approximately $3,423,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.